pharma · Diabetes · Congenital Bleeding Disorder
Novo Nordisk A/S
Novo Nordisk is a pharma organization headquartered in bagsværd, DK. Primary therapeutic focus areas include Diabetes, Congenital Bleeding Disorder, Acquired Bleeding Disorder, Overweight, Cardiorespiratory arrest at bir
Novo Alle, Bagsværd, 2880, DK HQ
1923 Founded
63,033 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Novo Alle, Bagsværd, 2880, DK
- Founded
- 1923
- Employees
- 63,033
- Programs
- 40
- Drugs
- 46
- Patents
- 0
Tecentriq 840 mg concentrate for solution for infusion
Phase 3 · small molecule · Metastatic pancreatic ductal adenocarcinoma (mPDAC)
Tecentriq 840 mg concentrate for solution for infusion for Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a Phase 3 program (small_molecule) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).
Internal code EF-39
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Novo Nordisk A/S
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Metastatic pancreatic ductal adenocarcinoma (mPDAC)
- Status
- active
- Trials
- 1